Patents Assigned to Gilead Calistoga LLC
  • Patent number: 10154998
    Abstract: The invention provides methods that relate to a novel therapeutic strategy for the treatment of hematological malignancies and inflammatory diseases. In particular, the method comprises administering a compound of formula A, wherein R is H, halo, or C1-C6 alkyl; R? is C1-C6 alkyl; or a pharmaceutically acceptable salt thereof; and optionally a pharmaceutically acceptable excipient; and administering at least one additional therapeutic agent.
    Type: Grant
    Filed: September 27, 2016
    Date of Patent: December 18, 2018
    Assignee: Gilead Calistoga LLC
    Inventors: W. Michael Gallatin, Roger G. Ulrich, Neill A. Giese, Brian Lannutti, Langdon Miller, Thomas M. Jahn
  • Patent number: 10059677
    Abstract: A process for the synthesis of benzoxazinone containing compounds which may be useful precursors for synthesizing compounds for the treatment of cancer, is hereby disclosed.
    Type: Grant
    Filed: December 28, 2016
    Date of Patent: August 28, 2018
    Assignee: Gilead Calistoga LLC
    Inventors: Stacy Bremner, Jerry Evarts, Keiko Sujino, Duong Tran, Dragos Vizitiu
  • Patent number: 10047060
    Abstract: A process for the synthesis of quinazolinone containing compounds which may be useful for the treatment of cancer, is hereby disclosed. In addition, compound intermediates relating to these processes are also disclosed.
    Type: Grant
    Filed: November 17, 2017
    Date of Patent: August 14, 2018
    Assignee: Gilead Calistoga LLC
    Inventors: Stacy Bremner, Jerry Evarts, Keiko Sujino, Duong Tran, Dragos Vizitiu
  • Patent number: 9708327
    Abstract: Polymorphs of a hydrochloride salt of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one, compositions thereof, methods for their preparation, and methods for their use are disclosed. Solvent forms of a hydrochloride salt of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one, compositions thereof, methods for their preparation, and methods for their use are also disclosed.
    Type: Grant
    Filed: December 18, 2014
    Date of Patent: July 18, 2017
    Assignee: GILEAD CALISTOGA LLC
    Inventors: Suzanne Buttar, Ernest Carra, Tracy Ehiwe, Duong Tran, Fang Wang, Christopher Worrall, Jerry Evarts
  • Patent number: 9492449
    Abstract: The invention provides methods that relate to a novel therapeutic strategy for the treatment of hematological malignancies and inflammatory diseases. In particular, the method comprises administering a compound of formula A, wherein R is H, halo, or C1-C6 alkyl; R? is C1-C6 alkyl; or a pharmaceutically acceptable salt thereof; and optionally a pharmaceutically acceptable excipient; and administering at least one additional therapeutic agent.
    Type: Grant
    Filed: March 9, 2012
    Date of Patent: November 15, 2016
    Assignee: Gilead Calistoga LLC
    Inventors: W. Michael Gallatin, Roger G. Ulrich, Neill A. Giese, Brian Lannutti, Langdon Miller, Thomas M. Jahn
  • Patent number: 9469643
    Abstract: Polymorphs of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one, compositions thereof, methods for their preparation, and methods for their use are disclosed.
    Type: Grant
    Filed: September 22, 2014
    Date of Patent: October 18, 2016
    Assignee: Gilead Calistoga, LLC.
    Inventors: Ernest Carra, Michael Gerber, Bing Shi, Keiko Sujino, Duong Tran, Fang Wang, Jerry B. Evarts
  • Patent number: 9266878
    Abstract: The present disclosure provides phosphatidylinositol 3-kinase (PI3K) inhibitors of formula (I), or pharmaceutically acceptable salts thereof, in which R1, R2, n, R3, R4, R5 and R6 are as defined herein. These compounds are useful for treatment of conditions mediated by one or more PI3K isoforms, such as PI3K?. The present disclosure further provides pharmaceutical compositions that include a compound of formula (I), or pharmaceutically acceptable salts thereof, and methods of using these compounds and compositions to treat conditions mediated by one or more PI3K isoforms, such as PI3K?.
    Type: Grant
    Filed: April 14, 2015
    Date of Patent: February 23, 2016
    Assignee: Gilead Calistoga LLC
    Inventors: Jerry Evarts, Leena Patel, Jennifer A. Treiberg, Stephane Perreault, Arthur Yeung, Lafe J. Purvis, II, Musong Kim
  • Patent number: 9238070
    Abstract: The invention provides methods that relate to a novel therapeutic strategy for the treatment of hematological malignancies and inflammatory diseases. In particular, the method comprises administration of a compound of formula A, wherein R is H, halo, or C1-C6 alkyl; R? is C1-C6 alkyl; or a pharmaceutically acceptable salt thereof; and optionally a pharmaceutically acceptable excipient.
    Type: Grant
    Filed: February 7, 2013
    Date of Patent: January 19, 2016
    Assignee: Gilead Calistoga LLC
    Inventors: W. Michael Gallatin, Roger G. Ulrich, Neill A. Giese
  • Publication number: 20150218154
    Abstract: The present disclosure provides phosphatidylinositol 3-kinase (PI3K) inhibitors of formula (I), or pharmaceutically acceptable salts thereof, in which R1, R2, n, R3, R4, R5 and R6 are as defined herein. These compounds are useful for treatment of conditions mediated by one or more PI3K isoforms, such as PI3K?. The present disclosure further provides pharmaceutical compositions that include a compound of formula (I), or pharmaceutically acceptable salts thereof, and methods of using these compounds and compositions to treat conditions mediated by one or more PI3K isoforms, such as PI3K?.
    Type: Application
    Filed: April 14, 2015
    Publication date: August 6, 2015
    Applicant: Gilead Calistoga LLC
    Inventors: Jerry Evarts, Leena Patel, Jennifer A. Treiberg, Stephane Perreault, Arthur Yeung, Lafe J. Purvis, II, Musong Kim
  • Patent number: 9029384
    Abstract: The present disclosure provides phosphatidylinositol 3-kinase (PI3K) inhibitors of formula (I), or pharmaceutically acceptable salts thereof, in which n, m, R1, R2, and R3 are as defined herein. These compounds are useful for treatment of conditions mediated by one or more PI3K isoforms, such as PI3K?. The present disclosure further provides pharmaceutical compositions that include a compound of formula (I), or pharmaceutically acceptable salts thereof, and methods of using these compounds and compositions to treat conditions mediated by one or more PI3K isoforms, such as PI3K?.
    Type: Grant
    Filed: December 20, 2013
    Date of Patent: May 12, 2015
    Assignee: Gilead Calistoga, LLC.
    Inventors: Jerry Evarts, Leena Patel, Joshua Kaplan, Jennifer A. Treiberg, Stephane Perreault, Gary Phillips
  • Patent number: 9018221
    Abstract: The present disclosure provides phosphatidylinositol 3-kinase (PI3K) inhibitors of formula (I), or pharmaceutically acceptable salts thereof, in which R1, R2, n, R3, R4, R5 and R6 are as defined herein. These compounds are useful for treatment of conditions mediated by one or more PI3K isoforms, such as PI3K?. The present disclosure further provides pharmaceutical compositions that include a compound of formula (I), or pharmaceutically acceptable salts thereof, and methods of using these compounds and compositions to treat conditions mediated by one or more PI3K isoforms, such as PI3K?.
    Type: Grant
    Filed: December 20, 2013
    Date of Patent: April 28, 2015
    Assignee: Gilead Calistoga, LLC
    Inventors: Jerry Evarts, Leena Patel, Jennifer A. Treiberg, Stephane Perreault, Arthur Yeung, Lafe J. Purvis, II, Musong Kim
  • Publication number: 20150080572
    Abstract: Polymorphs of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one, compositions thereof, methods for their preparation, and methods for their use are disclosed.
    Type: Application
    Filed: September 22, 2014
    Publication date: March 19, 2015
    Applicant: GILEAD CALISTOGA LLC
    Inventors: Ernest CARRA, Michael GERBER, Bing SHI, Keiko SUJINO, Duong TRAN, Fang WANG, Jerry B. EVARTS
  • Patent number: 8865730
    Abstract: Polymorphs of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one, compositions thereof, methods for their preparation, and methods for their use are disclosed.
    Type: Grant
    Filed: March 5, 2013
    Date of Patent: October 21, 2014
    Assignee: Gilead Calistoga LLC
    Inventors: Ernest Carra, Michael Gerber, Bing Shi, Keiko Sujino, Duong Tran, Fang Wang, Jerry B. Evarts
  • Publication number: 20140179673
    Abstract: The present disclosure provides phosphatidylinositol 3-kinase (PI3K) inhibitors of formula (I), or pharmaceutically acceptable salts thereof, in which R1, R2, n, R3, R4, R5 and R6 are as defined herein. These compounds are useful for treatment of conditions mediated by one or more PI3K isoforms, such as PI3K?. The present disclosure further provides pharmaceutical compositions that include a compound of formula (I), or pharmaceutically acceptable salts thereof, and methods of using these compounds and compositions to treat conditions mediated by one or more PI3K isoforms, such as PI3K?.
    Type: Application
    Filed: December 20, 2013
    Publication date: June 26, 2014
    Applicant: GILEAD CALISTOGA LLC
    Inventors: Jerry EVARTS, Leena PATEL, Jennifer A. TREIBERG, Stephane PERREAULT, Arthur YEUNG, Lafe J. PURVIS, II, Musong KIM
  • Publication number: 20140179718
    Abstract: The present disclosure provides phosphatidylinositol 3-kinase (PI3K) inhibitors of formula (I), or pharmaceutically acceptable salts thereof, in which n, m, R1, R2, and R3 are as defined herein. These compounds are useful for treatment of conditions mediated by one or more PI3K isoforms, such as PI3K?. The present disclosure further provides pharmaceutical compositions that include a compound of formula (I), or pharmaceutically acceptable salts thereof, and methods of using these compounds and compositions to treat conditions mediated by one or more PI3K isoforms, such as PI3K?.
    Type: Application
    Filed: December 20, 2013
    Publication date: June 26, 2014
    Applicant: GILEAD CALISTOGA LLC
    Inventors: Jerry EVARTS, Leena PATEL, Joshua KAPLAN, Jennifer A. TREIBERG, Stephane PERRAULT, Gary PHILLIPS
  • Patent number: 8691829
    Abstract: The invention provides methods to treat certain liver disorders by administering a compound that inhibits PD K isoforms, particularly the delta isoform. It further provides specific compounds useful for these methods and ways to identify subjects who are particularly suitable for receiving these treatments.
    Type: Grant
    Filed: July 21, 2010
    Date of Patent: April 8, 2014
    Assignee: Gilead Calistoga LLC
    Inventor: Roger G. Ulrich
  • Publication number: 20140066386
    Abstract: The invention provides methods that relate to a novel therapeutic strategy for the treatment of hematological malignancies and inflammatory diseases. In particular, the method comprises administration of a compound of formula A, wherein R is H, halo, or C1-C6 alkyl; R? is C1-C6 alkyl; or a pharmaceutically acceptable salt thereof; and optionally a pharmaceutically acceptable excipient.
    Type: Application
    Filed: February 7, 2013
    Publication date: March 6, 2014
    Applicant: GILEAD CALISTOGA LLC
    Inventor: Gilead Calistoga LLC
  • Publication number: 20140051696
    Abstract: Provided herein are methods that relate to a novel therapeutic strategy for treatment of cancer, including hematological malignancies such as leukemia, lymphoma, and multiple myeloma. In particular, the method includes administration of a PI3K? inhibitor and a Syk inhibitor.
    Type: Application
    Filed: August 14, 2013
    Publication date: February 20, 2014
    Applicant: GILEAD CALISTOGA LLC
    Inventors: Brian J. LANNUTTI, Julie DI PAOLO, Heather WEBB, Adam KASHISHIAN
  • Publication number: 20130344138
    Abstract: The invention provides methods that relate to a novel therapeutic strategy for the treatment of hematological malignancies and inflammatory diseases. In particular, the method comprises administration of a compound of formula I, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising such compound admixed with at least one pharmaceutically acceptable excipient.
    Type: Application
    Filed: August 28, 2013
    Publication date: December 26, 2013
    Applicant: GILEAD CALISTOGA LLC
    Inventors: Kamal D. PURI, Jerry B. EVARTS, Brian LANNUTTI, Neill GIESE
  • Patent number: 8546409
    Abstract: The invention provides methods that relate to a novel therapeutic strategy for the treatment of hematological malignancies and inflammatory diseases. In particular, the method comprises administration of a compound of formula I, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising such compound admixed with at least one pharmaceutically acceptable excipient.
    Type: Grant
    Filed: April 20, 2010
    Date of Patent: October 1, 2013
    Assignee: Gilead Calistoga LLC
    Inventors: Kamal D. Puri, Jerry B. Evarts, Brian Lannutti, Neill Giese